Table 3.
Description of patients without fibrosis/cirrhosis at baseline progressing to F3–F4 fibrosis by the end of follow-up.
| No progression (n = 100) | Progression to F3–F4 (n = 20) | Pc | |
|---|---|---|---|
| At baseline | |||
| Male gendera | 76 (76.0) | 20 (100) | 0.01 |
| Age >40 yearsa | 43 (43.0) | 17 (85.0) | 0.001 |
| BMI (kg/m2)b | 22.7 (21.0–24.8) | 23.6 (21.4–24.5) | 0.4 |
| Zone of high HBV-endemicitya | 35 (35.0) | 1 (5.0) | 0.007 |
| Alcohol consumption (glasses/day)a | 0.10 | ||
| 0 | 44 (50.6) | 5 (26.3) | |
| >0–2 | 22 (25.3) | 9 (47.4) | |
| >2 | 21 (24.1) | 5 (26.3) | |
| Cardiovascular diseasea | 12 (12.0) | 4 (20.0) | 0.5 |
| Diabetesa | 3 (3.0) | 0 | 0.9 |
| Fasting glycaemia (mmol/L)b | 4.9 (4.6–5.4) | 5.2 (5.0–5.6) | 0.03 |
| Fasting triglycerides (mmol/L)b | 1.30 (0.90–2.09) | 1.46 (1.06–1.89) | 0.9 |
| AIDS-defining illnessa | 20 (20.0) | 6 (30.0) | 0.3 |
| CD4+ cell count (/mm3)b | 404 (320–576) | 367 (229–520) | 0.19 |
| CD4+ cell count (≥350/mm3)a | 71 (71.0) | 10 (50.0) | 0.07 |
| Nadir CD4+ cell count (/mm3)b | 237 (116–365) | 186 (32–242) | 0.03 |
| Nadir CD4+ (≥250/mm3)a | 43 (45.7) | 2 (11.8) | 0.01 |
| HIV-RNA (<50 copies/mL)a | 52 (52.5) | 12 (60.0) | 0.6 |
| ART duration (years)b | 5.9 (3.4–8.6) | 6.8 (5.5–9.9) | 0.2 |
| PI-containing ARTa | 40 (40.0) | 12 (60.0) | 0.10 |
| HBV-DNA (log10 IU/mL)b | 4.55 (2.17–6.88) | 2.95 (2.42–5.27) | 0.4 |
| HBV-DNA (<60 IU/mL)a | 22 (22.2) | 3 (15.0) | 0.6 |
| HBeAg-positivea | 60 (60.0) | 14 (70.0) | 0.5 |
| ALT >2 × ULNa | 23 (23.2) | 4 (20.0) | 0.9 |
| Prothrombin timeb | 93 (86–100) | 90 (83–100) | 0.6 |
| Platelet count (109/L)b | 202 (170–247) | 163 (135–243) | 0.11 |
| <150 (109/L)a | 13 (13.1) | 8 (40.0) | 0.004 |
| Albumin (g/L)b | 43.0 (39.7–46.0) | 43.5 (40.0–45.5) | 0.6 |
| <36 g/La | 13 (13.0) | 0 (0) | 0.12 |
| Hyaluronic acid (µg/mL)b | 31 (19–53) | 35 (22–70) | 0.2 |
| Previous LAM-usea | 85 (85.0) | 19 (95.0) | 0.3 |
| Mutations at position rt204a,d | 41 (41.0) | 6 (30.0) | 0.4 |
| At end of follow-up | |||
| TDF duration (months)b | 48 (28–86) | 63 (26–100) | 0.18 |
| HBV-DNA (<60 IU/mL)a | 79 (79.0) | 18 (90.0) | 0.4 |
| HBeAg-seroclearancea,e | 11 (18.3) | 6 (42.9) | 0.05 |
| HBsAg-seroclearancea,f | 2 (2.0) | 0 | 0.9 |
| ALT >2 × ULNa | 4 (4.0) | 3 (15.0) | 0.06 |
| AST >2 × ULNa | 3 (3.1) | 2 (10.0) | 0.2 |
| Prothrombin timeb | 95 (91–100) | 90 (84–100) | 0.2 |
| Platelet count (109/L)b | 207 (182–246) | 179 (161–229) | 0.18 |
| <150 (109/L)a | 12 (12.1) | 3 (15.0) | 0.7 |
| Albumin (g/L)b | 43.0 (39.7–46.2) | 41.2 (39.8–43.7) | 0.10 |
| <36 g/La | 6 (6.3) | 0 | 0.6 |
| Hyaluronic acid (µg/mL)b | 24 (16–32) | 31 (16–47) | 0.16 |
| Fasting glycaemia (mmol/L)b | 5.0 (4.7–5.4) | 5.6 (5.0–5.8) | 0.008 |
| Fasting triglycerides (mmol/L)b | 1.15 (0.93–1.67) | 1.38 (0.97–2.49) | 0.16 |
| HIV-RNA (<50 copies/mL)a | 83 (83.8) | 19 (95.0) | 0.3 |
| Change in CD4+ cell countb | 139 (−14, 243) | 66 (−53, 220) | 0.5 |
| CD4+ cell count (≥500/mm3)a | 59 (60.2) | 8 (40.0) | 0.10 |
aNumber (%).
bMedian (IQR).
cSignificance between progression groups determined using Kruskal–Wallis test for continuous variables and Pearson’s χ 2 test or Fisher’s exact test for categorical variables.
dPatients without documented resistance were considered not to have any rt204 mutations.
eOnly HBeAg-positive patients; two patients without progression seroreverted HBeAg-positive after seroclearance.
fOne patient without progression seroreverted HBsAg-positive after seroclearance.